1303587-97-4

Basic information

• Product Name: 6-chloro-3,4-dihydro-2h-pyrido[3,2-b][1,4]oxazine
• Synonyms: 6-chloro-3,4-dihydro-2h-pyrido[3,2-b][1,4]oxazine;2H-Pyrazino[2,3-b]-1,4-oxazine, 6- chloro-3,4-dihydro-
• CAS NO: 1303587-97-4
• Molecular Formula: C₆H₆ClN₃O
• Molecular Weight: 170.59628
• Mol File: 1303587-97-4.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 315.5±42.0 °C(Predicted)
• Appearance: /
• Density: 1.409±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 1.21±0.20(Predicted)
• CAS DataBase Reference: 6-chloro-3,4-dihydro-2h-pyrido[3,2-b][1,4]oxazine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-3,4-dihydro-2h-pyrido[3,2-b][1,4]oxazine(1303587-97-4)
• EPA Substance Registry System: 6-chloro-3,4-dihydro-2h-pyrido[3,2-b][1,4]oxazine(1303587-97-4)

Safety Data

• Hazardous Substances Data: 1303587-97-4(Hazardous Substances Data)

Usage

Structure

Heterocyclic compound containing a pyrido[3,2-b][1,4]oxazine ring

Pharmaceutical Properties

Investigated for potential pharmaceutical use

Antineoplastic Potential

Studied for possible anti-cancer properties

Interest in Medicinal Chemistry

Considered as a novel drug candidate

Research Need

Further studies required to fully understand its properties and applications

Upstream product

• 1303587-96-3 3-amino-5-chloropyrazin-2-ol 
• 106-93-4 ethylene dibromide 

Downstream Products

• 1303587-98-5 6-(3-(trifluoromethyl)phenyl)-3,4-dihydro-2H-pyrazino[2,3-b][1,4]oxazine 
• 1303586-08-4 N-(4-methylthiazol-2-yl)-6-(3-(trifluoromethyl)phenyl)-2H-pyrazino[2,3-b][1,4]oxazine-4(3H)-carboxamide 

Relevant articles and documents

BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.